# NIH Reporter #7R01CA292084-02

Pharmacodynamically directed targeted therapy for leukemia

**Recipient:** University of Pittsburgh at Pittsburgh

**Award Amount:** $694,315.00
**Ceiling:** $694,315.00

**Awarded:** September 08, 2026

**Identifier:** 7R01CA292084-02

NIH awarded $694,315 to University of Pittsburgh for developing a targeted therapy for AML using DHODH inhibitor HOSU-53, focusing on TP53 mutated cases, including clinical trials and advanced monitoring techniques.

### Description

This project aims to develop a targeted therapy using a potent DHODH inhibitor (HOSU-53) for Acute Myeloid Leukemia (AML), focusing on TP53 mutated AML. It includes preclinical development, IND enabling studies, and the first-in-human clinical trial with pharmacokinetic, pharmacodynamic, and single-cell DNA sequencing monitoring.

[View original record](https://reporter.nih.gov/search/0C83gI3MXki4-tEhFD4UKQ/project-details/11611081)